HC Wainwright & Co. Initiates Coverage On Ascendis Pharma with Buy Rating, Announces Price Target of $345
Ascendis Pharma A/S
Ascendis Pharma A/S ASND | 0.00 |
HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Ascendis Pharma (NASDAQ:
ASND) with a Buy rating and announces Price Target of $345.
